Intellia Therapeutics, Inc. Form SC 13G/A February 12, 2018

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G

(Rule 13d-102)

Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. 1)*

INTELLIA THERAPUTICS, INC.

(Name of Issuer)

Common Stock, \$0.0001

(Title of Class of Securities)

45826J105

(CUSIP Number)

December 31, 2017

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- o Rule 13d-1(b)
- o Rule 13d-1(c)
- x Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 45826J1	05			13G
1.	Name of Reporting Person S.S. or I.R.S. Identification No. of Above Person Atlas Venture Fund IX, L.P.			
2.	Check the Appropriate B (a) (b)	Box if a Member o o o	of a Group*	
3.	SEC Use Only			
4.	Citizenship or Place of C Delaware	Organization		
	5.		Sole Voting Power	
Number of Shares Beneficially Owned by	6.		Shared Voting Power 3,579,788	
Each Reporting Person With	7.		Sole Dispositive Power	
Person with	8.		Shared Dispositive Power 3,579,788	
9.	Aggregate Amount Beneficially Owned by Each Reporting Person 3,579,788			
10.	Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares o			
11.	Percent of Class Represented by Amount in Row (9) 8.45%			
12.	Type of Reporting Perso PN	n*		

2

Edgar Filing: Intellia Therapeutics, Inc. - Form SC 13G/A

1.	Name of Reporting Person			
	S.S. or I.R.S. Identification No. of Above Person Atlas Venture Associates IX, L.P.			
2.	Check the Appropriate Box if a Member of a Group*			
	(a) 0	F		
	(b) o			
3.	SEC Use Only			
4.	Citizenship or Place of Organization Delaware			
	5.		Sole Voting Power	
Number of				
Shares	6.		Shared Voting Power	
Beneficially Owned by			3,579,788	
Each	7.		Sole Dispositive Power	
Reporting Person With			ŗ	
	8.		Shared Dispositive Power 3,579,788	
9.	Aggregate Amount Beneficially Owned by Each Reporting Person 3,579,788			
10.	Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares o			
11.	Percent of Class Represented by Amount in Row (9) 8.45%			
12.	Type of Reporting Person* PN			

3

Edgar Filing: Intellia Therapeutics, Inc. - Form SC 13G/A

1.	Name of Reporting Person S.S. or I.R.S. Identification No. of Above Person Atlas Venture Associates IX, LLC		
2.		ate Box if a Member of a G	iroup*
	(a) (b)	0 0	
3.	SEC Use Only		
4.	Citizenship or Place Delaware	of Organization	
	5.		Sole Voting Power
Number of Shares Beneficially Owned by	6.		Shared Voting Power 3,579,788
Each Reporting Person With	7.		Sole Dispositive Power
	8.		Shared Dispositive Power 3,579,788
9.	Aggregate Amount Beneficially Owned by Each Reporting Person 3,579,788		
10.	Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares o		
11.	Percent of Class Represented by Amount in Row (9) 8.45%		
12.	Type of Reporting P OO	'erson*	

4

CUSIP No. 45826J105 SCHEDULE 13G		LE 13G		
Item 1(a).		Name of Issuer		
Item 1(b).		The name of the issuer to which this filing on Schedule 13G relates is Intellia Therapeutics, Inc. (the <u>Company</u>). Address of Issuer s Principal Executive Offices		
		The principal executive offices of the Company are located at 40 Erie Street, Suite 130, Cambridge, Massachusetts 02139.		
Item 2(a).		Name of Person Filing		
Item 2(b).		This Statement is being filed on behalf of Atlas Venture Fund IX, L.P. (<u>Atlas IX</u>), Atlas Venture Associates IX, L.P. (<u>AVA IX LP</u>), the sole general partner of Atlas IX, and Atlas Venture Associates IX, LLC (<u>AVA IX LLC</u>), the sole general partner of AVA IX LP. Address of Principal Business Office or, if none, Residence		
Item 2(c).		The principal business address of each of Atlas IX, AVA IX LP, and AVA IX LLC is 25 First Street, Suite 303, Cambridge, MA 02141. Citizenship		
Item 2(d).		Each of Atlas IX, AVA IX LP and AVA IX LLC is organized under the laws of Delaware. Title of Class of Securities		
Item 2(e).		The class of equity securities of the Company to which this filing on Schedule 13G relates is Common Stock, par value \$0.0001 (<u>Common Stock</u>). CUSIP Number		
		The CUSIP number of the Company s Common Stock is 45826J105.		
Item 3.	If this statement is f Not applicable.	iled pursuant to §§240.13d-1()	b) or 240.13d-2(b) or (c), check whether the person filing is a:	
	(a)	0	Broker or dealer registered under section 15 of the Act (15 U.S.C. 780).	
	(b)	0	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 73c).	
	(c)	0	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).	
	(d)	0	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).	
	(e)	0	An investment adviser in accordance with \$13d-1(b)(1)(ii)(E).	
	(f)	0	An employee benefit plan or endowment fund in accordance with \$240.13d-1(b)(1)(ii)(F).	
	(g)	0	A parent holding company or control person in accordance with \$240.13d-1(b)(1)(ii)(G).	
	(h)	0	A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).	
	(i)	0	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).	
	(j)	0	Group, in accordance with §240.13d-1(b)(1)(ii)(J).	
		0	If this statement is filed pursuant to §240.13d-1(c), check this box.	

CUSIP No. 45826J105		SCHEDULE 13G		
Item 4.	Ownership			
Item 4(a).		Amount beneficially owned		
Item 4(b).		As of the close of business on December 31, 2017, Atlas IX is the record holder of 3,579,788 shares of Common Stock (the <u>Atlas Shares</u>). AVA IX LP is the sole general partner of Atlas IX. AVA IX LLC is the sole general partner of AVA IX LP. No person other than the respective owner referred to herein of the Atlas Shares is known to have the right to receive or the power to direct the receipt of dividends from or the proceeds from the sale of such Atlas Shares. Each of Atlas IX, AVA IX LP, and AVA IX LLC disclaim beneficial ownership of the Atlas Shares except for such shares, if any, such person holds of record. Percent of class		
Item 4(c).		As of the close of business on December 31, 2017, Atlas IX was the beneficial owner of 8.45% of the Common Stock. Number of shares as to which the person has:		

		Number of Shares	of Common Stock		
Reporting Person	(i)	(ii)	(iii)	(iv)	
Atlas IX	-0-	3,579,788	-0-	3,579,788	
AVA IX LP	-0-	3,579,788	-0-	3,579,788	
AVA IX LLC	-0-	3,579,788	-0-	3,579,788	
		(i) (ii)	Sole power to vo Shared power to		
		(iii)	Sole power to dis	spose or to direc	ct the disposition
		(iv)	Shared power to	dispose or to di	irect the disposition

Item 5. Not Applicable.	Ownership of Five Percent or Less of a Class
Item 6. Not Applicable.	Ownership of More than Five Percent on Behalf of Another Person
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company:
Not Applicable.	noning company.
Item 8.	Identification and Classification of Members of the Group

Edgar Filing: Intellia Therapeutics, Inc. - Form SC 13G/A

Not Applicable. The Filing Persons expressly disclaim membership in a group as used in Rule 13d-5(b)(1).

Item 9. Notice of Dissolution of Group

Not Applicable.

CUSIP No. 45826J105

SCHEDULE 13G

 Item 10.
 Certification

 Not Applicable. This statement on Schedule 13G is not filed pursuant to Rule 13d-1(b) or 13(d)-1(c).

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 9, 2018

ATLAS VENTURE FUND IX, L.P.

By: Atlas Venture Associates IX, L.P., its general partner By: Atlas Venture Associates IX, LLC, its general partner

By:

/s/ Frank Castellucci Name: Frank Castellucci Title: Secretary

ATLAS VENTURE ASSOCIATES IX, L.P. By: Atlas Venture Associates IX, LLC,

its general partner

By:

/s/ Frank Castellucci Name: Frank Castellucci Title: Secretary

ATLAS VENTURE ASSOCIATES IX, LLC

By:

/s/ Frank Castellucci Name: Frank Castellucci Title: Secretary

Exhibit A

Joint Filing Agreement

The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him, her or it contained herein, but shall not be responsible for the completeness and accuracy of the information concerning the other entities or persons, except to the extent that he, she or it knows or has reason to believe that such information is inaccurate.

Dated: February 9, 2018

ATLAS VENTURE FUND IX, L.P.

By: Atlas Venture Associates IX, L.P., its general partner By: Atlas Venture Associates IX, LLC, its general partner

By:

/s/ Frank Castellucci Name: Frank Castellucci Title: Secretary

ATLAS VENTURE ASSOCIATES IX, L.P.

By: Atlas Venture Associates IX, LLC, its general partner

By:

/s/ Frank Castellucci Name: Frank Castellucci Title: Secretary

ATLAS VENTURE ASSOCIATES IX, LLC

By:

/s/ Frank Castellucci Name: Frank Castellucci Title: Secretary